. Harmful algal blooms are increasing worldwide, including those of Pseudo-nitzschia spp. producing domoic acid off the California coast. This neurotoxin was first shown to cause mortality of marine mammals in 1998. A decade of monitoring California sea lion (Zalophus californianus) health since then has indicated that changes in the symptomatology and epidemiology of domoic acid toxicosis in this species are associated with the increase in toxigenic blooms. Two separate clinical syndromes now exist: acute domoic acid toxicosis as has been previously documented, and a second
novel neurological syndrome characterized by epilepsy described here associated with chronic consequences of previous sub-lethal exposure to the toxin. This study indicates that domoic acid causes chronic damage to California sea lions and that these health effects are increasing.
COMMENTARY
T he kainic acid model of experimental epilepsy has yielded a detailed understanding of some of the processes involved in epileptogenesis and the generation of spontaneous recurrent seizures (1) . When administered systemically or intracerebroventricularly in animal models, kainic acid produces an epilepsy syndrome similar to human temporal lobe epilepsy. Experimental animals treated acutely with kainic acid develop status epilepticus with seizure onset in the hippocampus. After a latent period of days to weeks, these animals begin to exhibit spontaneous, recurrent limbic seizures-the hallmark of the epileptic state (2) . Much like the human syndrome, there are histopathological changes, including cell death in hippocampal subregions CA1, CA3, and the dentate hilus, with sparing of the dentate gyrus reminiscent of human mesial temporal sclerosis. In addition, axonal reorganization in the form of dentate mossy fiber sprouting is one factor that produces a hyperexcitable circuit underlying the seizure-prone state. Finally, animals develop a variety of behavioral and cognitive abnormalities that resemble human temporal lobe epilepsy. Kainic acid acts via glutamatergic ionotropic kainic acid and AMPA receptors to initiate an excitatory cascade that produces these neurological sequelae (3) . This report by Goldstein et al. provides an unexpected, real-life context by which to view the kainic acid model. Domoic acid and kainic acid are excitotoxic glutamate analogs with close structural and pharmacologic similarities. These compounds, first identified 50 years ago in algal seaweeds of Japan, were used initially to treat roundworm disease. In 1978, 103 individuals were poisoned by eating shellfish (harvested from Prince Edward Island, Canada) contaminated with domoic acid (4) . The contamination originated from a rapidly increasing algal bloom (5) . In the Canadian outbreak, affected individuals developed seizures, agitation, confusion, memory deficits, and gastrointestinal distress; a few people died. Histopathology demonstrated hippocampal sclerosis. One subject who survived the acute poisoning event developed complex partial seizures with hippocampal sclerosis a year later, supporting a role for excitotoxicity in epileptogenesis (6) .
Laboratory studies of domoic acid induce features in rodents and primates that parallel human symptoms, demonstrating that this compound causes excitotoxicity and damage to neuronal pathways responsible for learning, spatial memory, and seizure generation (7) . However, experimental research using domoic acid has lagged behind studies using kainic acid in terms of defining the spectrum of clinical sequelae and pathogenetic mechanisms.
Shifting offshore winds and ocean upwellings fueled by climate oscillations off the California coast have initiated a decade of harmful algal blooms that produce domoic acid. The first major event, occurring in 1998, caused glutamatergic excitotoxity resulting in status epilepticus, subsequent hippocampal damage, and mass mortality of California sea lions (8) . Goldstein and coworkers examined the epidemiology of 715 California Epilepsy Currents, Vol. 9, No. 5 (September/October) 2009 pp. 142-143 Wiley Periodicals, Inc. C American Epilepsy Society sea lions with clinical signs of domoic acid poisoning that were stranded between 1998 and 2006. The term stranded refers to the death of an animal or its inability to return to its natural ocean habitat as a result of poor health or injury. In the present report, the authors documented both acute and chronic domoic acid toxicity, providing evidence that the acute toxicity leads to chronic disease. Over this 8-year period, three-quarters of the surviving stranded sea lions exhibited acute domoic acid toxicosis, with seizures, ataxia, or coma. The remaining animals exhibited a novel chronic epilepsy syndrome, characterized by behavioral abnormalities and recurrent limbic seizures similar to that observed in laboratory rodents and humans with temporal lobe epilepsy. The number of stranded sea lions exhibiting chronic epilepsy increased each year after a major algal bloom, with an estimated 4-month lag time between acute events and appearance of chronic symptoms. Additionally, clinical observations revealed that a subset of 32 animals admitted for acute poisoning by domoic acid developed chronic epilepsy after a latent period in captivity of 16 to 85 days.
An epizootic, defined as an epidemic outbreak of disease in an animal population, has major health implications for multiple species. Together, the epidemiological and clinical findings implicate domoic acid in a wildlife epilepsy epizootic. Decades of kainic acid use in epilepsy research provide a rich source of information to understand this chronic neurological epizootic and its high lethality rates (9) . The development of epilepsy after a latent period is typical of severe kainic acid poisoning, but large epizootics of late-term fetal poisoning also occurred in the sea lions (10) . An unusually high degree of fetal brain maturation and slow amniotic fluid clearance of domoic acid enhance the potential for a form of in utero chemical kindling in fetal sea lions as a consequence of repeated algal blooms (11, 12) . The effects of kainic acid on memory and behavior also may provide a basis to better understand the unusual behaviors of domoic acid-exposed sea lions. As described by Goldstein et al., some affected animals exhibited bizarre behaviors, such as climbing onto a police car, walking along a road, and appearing in a field 100 miles inland. The sea lions also manifested repetitive behaviors and abnormal aggression toward conspecifics and humans.
Researchers studying harmful algal blooms have sought insight from biomedical and clinical research to explain symptoms observed in the natural environment off the California coast. They have designated the integration of data from both laboratory animals and the diseased sea lions with data from humans as a key element in their 10-year strategic plan for research and response (13) . The kainic acid model of epilepsy provides a basic science foundation for understanding this emerging chronic marine disease. Reciprocally, the emerging domoic acid epilepsy syndrome in California sea lions offers new information to expand the relevance of the kainic acid epilepsy model beyond the laboratory, where it can be investigated in populations of individuals who are amenable to brain imaging techniques in a clinical setting. This phenomenon reinforces the interaction among environmental events (such as harmful algal blooms) and the health of both marine animals and humans, as is recognized in the Oceans and Human Health Act of 2005 (HR 4818).
by John S. Ramsdell to the brain) is often considered to be a progressive disorder, and the nature of this hypothetical progression remains controversial.
Antiepileptic drug treatment necessarily confounds analyses of progressive changes in human patients with acquired epilepsy. Here, we describe experiments testing the hypothesis that development of acquired epilepsy begins as a continuous process of increased seizure frequency (i.e., proportional to probability of a spontaneous seizure) that ultimately plateaus. Using nearly continuous surface cortical and bilateral hippocampal recordings with radiotelemetry and semiautomated seizure detection, the frequency of electrographically recorded seizures (both convulsive and nonconvulsive) was analyzed quantitatively for 100 d after kainate-induced status epilepticus in adult rats. The frequency of spontaneous recurrent seizures was not a step function of time (as implied by the "latent period"); rather, seizure frequency increased as a sigmoid function of time. The distribution of interseizure intervals was nonrandom, suggesting that seizure clusters (i.e., short interseizure intervals) obscured the early stages of progression, and may have contributed to the increase in seizure frequency. These data suggest that (1) the latent period is the first of many long interseizure intervals and a poor measure of the time frame of epileptogenesis, (2) epileptogenesis is a continuous process that extends much beyond the first spontaneous recurrent seizure, (3) uneven seizure clustering contributes to the variability in occurrence of epileptic seizures, and (4) the window for antiepileptogenic therapies aimed at suppressing acquired epilepsy probably extends well past the first clinical seizure.
W ith most types of acquired epilepsy, an initial precipitating injury to the brain, such as head trauma, stroke, or an episode of status epilepticus, is the cause of the subsequent development of spontaneous, recurrent seizures. The interval between the original brain insult and the clinical presentation of the first seizure is commonly referred to as the latent period of epileptogenesis, which can often span months to years. During this latent period, the process of epileptogenesis occurs, as defined by abnormal changes in the molecular, cellular, and network properties of the brain that develop in response to the injury and ultimately are responsible for producing an epileptic state. From a therapeutic standpoint, while current seizure medications only act to suppress seizures symptomatically, this latent period offers a window of opportunity for initiating potential antiepileptogenic therapies in an attempt to prevent epilepsy from developing in the first place. While many assumptions have been made about the biological mechanisms and clinical implications of epileptogenesis during the latent period, recent work suggests that the conventional concept of the latent period of epileptogenesis may need to be revised.
In the traditional theory, the biological processes mediating epileptogenesis are completed exclusively during the latent period, such that the first seizure heralds an abrupt, step-like transition to a fully mature, stable epileptic state. In this scenario, although seizure frequency might fluctuate in a random fashion, there would be no evidence of systematic or progressive worsening of seizures following the initial presentation of epilepsy. Furthermore, from a therapeutic standpoint, antiepileptogenic therapies would not be predicted to be beneficial, if initiated after the first seizure. An alternative theory postulates that epileptogenesis represents a more gradual, progressive development that extends beyond the latent period. Thus, seizures would be expected to become increasingly more frequent or severe, as a reflection of the underlying epileptogenic events. In the extreme, most controversial version of this viewpoint, seizures themselves may directly cause or contribute to further advancement of the epileptic process (i.e., seizures beget seizures). If the progression of seizures does continue beyond the latent period, then initiation of antiepileptogenic therapies could potentially benefit patients even after the initial clinical seizures.
While many types of epilepsy, such as idiopathic childhood absence epilepsy, typically show no signs of progression and often remit spontaneously, some acquired epilepsies, such as temporal lobe epilepsy associated with mesial temporal sclerosis, can exhibit progressive increases in seizure frequency or severity over time. However, objective documentation of seizure progression in human epilepsy is difficult and controversial, because it is complicated by a number of confounding factors, such as inaccurate seizure histories, the lack of long-term EEG data, and the use of antiepileptic drugs (1, 2) . Thus, animal models of epilepsy may prove useful in more accurately measuring the duration of the latent period and identifying evidence of systematic changes in seizure properties that reflect an underlying progression of epileptogenesis. The recent study by Williams et al. constructs a comprehensive, quantitative analysis of the latent period and the subsequent evolution of seizures using a popular rodent model of temporal lobe epilepsy triggered by an initial episode of status epilepticus. A series of low doses of kainate was administered to rats to induce repetitive convulsive seizures over at least 3 hours. The rats then received almost continuous video-EEG monitoring with radiotelemetry (typically for a minimum of 100 days after kainate injection) to identify the subsequent onset and progression of both nonconvulsive and convulsive spontaneous seizures. In all but one animal, nonconvulsive electrographic seizures first emerged within a median latency of 8 days following kainate administration and preceded the onset of convulsive seizures by about 1 week, indicating that a progression in seizure severity occurs following epileptogenesis in the kainate model. Furthermore, after the onset of the first seizure, there was a nonlinear, progressive increase in seizure frequency. Statistical fitting of the mean daily seizure frequencies from all rats over time revealed a sigmoid shaped curve, involving four stages: 1) an initial phase of no seizures (the latent period), 2) a second phase with a gradual increase in seizure frequency, during which the interseizure intervals were extremely variable and could be nearly as long as the latent period itself, 3) a third stage with an exponential increase in seizure frequency, and 4) a final plateau phase, in which seizure frequency stabilized at a maximal rate. In addition to these stereotypical changes in seizure frequency over time, there was evidence of nonrandom clustering of seizures that was superimposed upon and could mask the underlying increase in seizure frequency in individual animals. Overall, the main conclusion drawn from this study was that epileptogenesis does not represent a stepwise, absolute transition that culminates in the first seizure, but rather reflects a gradually progressive process that continues well beyond the latent period. Furthermore, the data suggest that the latent period and initial evolution of seizure frequency represent probabilistic functions, with the tendency for seizures to occur increasing slowly over time following a brain injury, as the underlying mechanisms of epileptogenesis mature.
This study provides solid evidence to challenge the traditional concept of the latent period of epileptogenesis; however, the findings are not entirely novel. A previous study documented increasing seizure frequency in the kainate model (3), although this finding was based on intermittent behavioral observations only and did not use uninterrupted video-EEG, as employed in the study by Williams and colleagues. Continuous video-EEG monitoring also has been used in a model of electrical stimulation-induced status epilepticus; these studies similarly found that the frequency of spontaneous seizures exhibited an initial increase and reached a plateau over time (4, 5) .
The progression of seizure frequency documented in the present and previous studies has a number of mechanistic implications. Although the Williams et al. study did not investigate the underlying biological mechanisms involved, presumably the observed increase in seizure frequency following the latent period indicates that mechanisms of epileptogenesis continue to be active after the first seizure occurs. A previous study was able to correlate progressive increases in seizure frequency with loss of hilar interneurons and severe mossy fiber sprouting in the dentate gyrus (5) . However, the findings are simply correlative and do not prove cause and effect. Furthermore, the Williams et al. study and the previous work did not address the long-standing controversy about whether seizures themselves contribute to further progression of epilepsy. Future studies are required to determine the mechanistic basis of progressive epileptogenesis.
The clinical implications for a theory of epileptogenesis that extends beyond the latent period are potentially very significant. Although no proven antiepileptogenic treatments have yet been developed for clinical use, it is usually assumed that any antiepileptogenic treatment must be initiated during the latent period in order to be effective. However, practical issues may make it difficult or undesirable to initiate therapy prior to the onset of epilepsy. Thus, if epileptogenesis does continue beyond the latent period, then antiepileptogenic therapies may still have beneficial effects after presentation of the first seizure and the window of opportunity for initiating antiepileptogenic therapies may be much larger than previously believed. Whether an inflammatory-vascular-BBB mechanism could apply to the lithium-pilocarpine model is unknown. LiCl facilitated seizures induced by low-dose pilocarpine by activation of circulating T-lymphocytes and mononuclear cells. Serum IL-1β levels increased and BBB damage occurred concurrently to increased theta EEG activity. These events occurred prior to SE induced by cholinergic exposure. SE was elicited by lithium and pilocarpine irrespective of their sequence of administration supporting a common pathogenetic mechanism. Since IL-1β is an etiologic trigger for BBB breakdown and its serum elevation occurs before onset of SE early after LiCl and pilocarpine injections, we tested the hypothesis that intravenous administration of IL-1 receptor antagonists (IL-1ra) may prevent pilocarpine-induced seizures. Animals pre-treated with IL-1ra exhibited significant reduction of SE onset and of BBB damage. Our data support the concept of targeting systemic inflammation and BBB for the prevention of status epilepticus.

E xperimental models of seizures and epilepsy have been in-
valuable for understanding of the basic mechanisms underlying ictogenesis and epileptogenesis as well as for developing new therapeutic options. It is, therefore, of utmost importance to know the pathophysiological basis of the experimental model and which human pathological situations it mimics.
One of the earliest and most frequently used models for evoking experimental status epilepticus and subsequent epilepsy is the systemic injection of pilocarpine in rodents (1) . Treatment of rats and mice with low doses of lithium chloride (LiCl, 3 mEq/kg), followed by pilocarpine (30 mg/kg) or with a high dose of pilocarpine alone (300-350 mg/kg), results in a severe seizure-brain damage syndrome. The use of LiCl was devised to improve animal survival, because with this combination, the dose of pilocarpine can be decreased by about 10-fold. Since pilocarpine acts on muscarinic receptors (2) and its convulsant actions are evoked in the presence of the peripherally acting muscarinic antagonist, methyl-scopolamine (1), the activation of the cholinergic system by pilocarpine in the brain is believed to be the initiating factor for triggering seizures. Various studies have characterized pilocarpine-induced seizures using both EEG analysis and behavioral observations. Although there is still debate on the initiation site(s) of seizures (i.e., the hippocampus and related limbic regions vs ventral forebrain) and the involvement of brain regions in neuropathology (i.e., the hippocampus as compared to predominant neocortical damage), these initial studies nevertheless garnered a consensus among basic scien-tists that this model is representative of temporal lobe epilepsy precipitated by convulsive status epilepticus.
Recently, novel findings raise the possibility that pilocarpine-induced seizures are not only the result of a direct cholinergic system activation in the brain, but also are derived from primary proinflammatory actions of pilocarpine involving the periphery. In 2007, Marchi and colleagues showed that pilocarpine causes acute peripheral proinflammatory changes leading to blood-brain barrier (BBB) leakage, prior to the onset of status epilepticus (3). Additionally, they showed that pilocarpine is poorly permeable to the BBB and fails to produce seizure activity in vitro when applied at concentrations identical to, or higher than, drug levels measured in the brain, in vivo. In brain slices or isolated guinea pig brain, seizure-like events could be evoked by pilocarpine only in the co-presence of elevated K + concentrations, mimicking actions that occur when BBB permeability function is compromised (3, 4) . Based on the premises established from previous work and showing that pilocarpine can directly activate muscarinic receptors on brain microvasculature and white blood cells (5,6), Marchi and colleagues reported the following three interesting findings:
• The proinflammatory mediator interleukin (IL)-1β is increased four-fold on average in serum shortly after pilocarpine injection and before the onset of status epilepticus; this effect was a consequence of white blood cell activation by pilocarpine.
• At the same time, there was a significant reduction in the number of CD4-expressing cells. These peripheral effects were not antagonized by methyl-scopolamine at the dose used to prevent the systemic actions of pilocarpine. • Before the onset of status epilepticus, BBB damage was observed as assessed by leakage of serum albumin into the brain parenchyma (3).
These initial investigations highlighting the peripheral proinflammatory effects of pilocarpine anticipated the present study by Marchi and collaborators, which demonstrates that peripheral inflammation is indeed the initial and required mechanism by which pilocarpine, or LiCl plus pilocarpine, triggers status epilepticus. Marchi and colleagues describe changes in peripheral markers of inflammation after the injection of 3 mEq/kg of LiCl alone, which are very similar to those previously described using full convulsant doses (350 mg/kg) of pilocarpine (3). In particular, Marchi and colleagues report a decrease in CD4:CD8 positive cells ratio and an increase in monocytes/macrophages, at 3 hours and 20 hours after LiCl injection, thus reflecting profound changes in peripheral immune cells. Moreover, a concomitant increase in serum IL-1β level was found to be similar to that induced by a full convulsant dose of pilocarpine; this phenomenon was associated with the evidence of albumin brain extravasation as an index of BBB leakage. These changes were accompanied by alteration in the EEG pattern consisting of a pronounced increase in 4-5 Hz activity and spike amplitude, as assessed 3 hours after LiCl administration. While the EEG synchronized to a burst firing pattern over time, no clinical seizures were observed.
Since IL-1β is elevated in serum early after pilocarpine or LiCl administration, it is an etiological factor in BBB breakdown (7) , and possesses proconvulsant activity when applied to the brain (8) , the authors set out to antagonize the effects of increased serum levels of IL-1β and to investigate the impact of this cytokine on pilocarpine's effects. They used the IL-1 receptor antagonist (IL-1Ra), which is an endogenous competitive antagonist of IL-1 type 1 receptors that inhibit the biological action of IL-1β. It has been previously shown that IL-1Ra mediates powerful anticonvulsant actions in different models of seizures (8) and that transgenic mice overexpressing IL-1Ra in astrocytes are less susceptible to seizures (9,10), thus establishing the crucial role of elevated brain levels of IL-1β in the mechanisms of ictogenesis (8, 9) . Marchi and colleagues used a systemic single bolus injection of IL-1Ra 2 hours before pilocarpine administration to antagonize the peripheral actions of IL-1β; they found a drastic reduction in the number of rats showing status epilepticus as well as in the severity of status epilepticus in those rats that still developed seizures in spite of the IL-1Ra treatment. Moreover, IL-1Ra prevented BBB breakdown following pilocarpine.
In summary, this set of data demonstrates that pilocarpine induces status epilepticus, via a primary peripheral effect on white blood cells, leading to elevated serum levels of IL-1β, which in turn alters BBB permeability. The ionic imbalance due to K + accumulation in the extracellular space, induced by BBB leakage, is required for pilocarpine to produce its convulsant activity by stimulation of muscarinic receptors in the brain. The possibility also exists that elevated serum levels of IL-1β contribute to lower seizure threshold to pilocarpine by a direct action of IL-1β on neurons (8) . Thus, serum IL-1β may enter the brain because of the BBB leakage or may prime its own synthesis and release by activating IL-1R type 1 on endothelial cells and adjacent perivascular astrocytes (10) .
These findings prompt reconsideration of the use of pilocarpine injections for evoking prolonged seizures as a model of peripheral inflammation prodromic to the onset of status epilepticus. The concept that peripheral inflammatory reactions contribute to lower seizure threshold was established a long time ago in studies demonstrating that systemic lipopolysaccharide (a component of the bacterial wall of Gram-negative bacteria mimicking infection) reduces the threshold to seizures in adult rodents (11) . Recently, lipopolysaccharide or intracolonic administration of 2,4,6-trinitrobenzene sulfonic acid (in a model of bowel disease), delivered to immature rats (postnatal day 7 or 14), was reported to induce long-lasting increases in seizure susceptibility and seizure-associated brain damage (12, 13) . Thus, systemic inflammation is associated in experimental models with modifications in seizure susceptibility that, when evoked in early infancy, persists well into adulthood.
Systemic inflammation may occur in a clinical setting and is often associated with fever, which subsequently may provoke seizures in children. Activation of the IL-1β system has been implicated in the mechanisms underlying experimental febrile seizures (14) . Pathological events, such as systemic or CNS infection, and febrile seizures appear to be associated with an increased risk for late unprovoked seizures, therefore warranting further investigations of the underlying mechanisms of increased brain excitability. In light of this novel information, the pilocarpine model of status epilepticus should be revisited for the study of status epilepticus associated with systemic inflammatory processes. In this framework, it may be a useful tool to investigate pharmacological interventions to stop seizures precipitated by systemic inflammatory causes (8, 10, 15) . inhibited acute seizure induction and chronic spontaneous recurrent seizures. Blood-brain barrier (BBB) leakage, which is known to enhance neuronal excitability, was induced by acute seizure activity but was prevented by blockade of leukocyte-vascular adhesion, suggesting a pathogenetic link between leukocyte-vascular interactions, BBB damage and seizure generation. Consistent with the potential leukocyte involvement in epilepsy in humans, leukocytes were more abundant in brains of individuals with epilepsy than in controls. Our results suggest leukocyte-endothelial interaction as a potential target for the prevention and treatment of epilepsy. Although lymphocytic-choriomeningitis-virus-specific cytotoxic T lymphocytes (CTLs) are essential for disease 4 , their mechanism of action is not known. To gain insights into disease pathogenesis, we observed the dynamics of immune cells in the meninges by two-photon microscopy. Here we report visualization of motile CTLs and massive secondary recruitment of pathogenic monocytes and neutrophils that were required for vascular leakage and acute lethality. CTLs expressed multiple chemoattractants capable of recruiting myelomonocytic cells. We conclude that a CD8 + T-cell-dependent disorder can proceed in the absence of direct T-cell effector mechanisms and rely instead on CTL-recruited myelomonocytic cells.
Myelomonocytic Cell Recruitment Causes Fatal CNS Vascular Injury during
Epilepsy Currents, Vol. 9, No. 5 (September/October) 2009 pp. 148-150 Wiley Periodicals, Inc. C American Epilepsy Society COMMENTARY E pileptogenesis has traditionally been regarded as a purely neurological phenomenon, with little or no input from outside the central nervous system (CNS). This perception of exclusivity, to some extent, has been reinforced because of the known functions of the blood-brain barrier (BBB) as a physical and metabolic barrier that maintains local brain homeostasis and affords protection from xenobiotics and circulating cells, while allowing passage of essential molecules, like glucose (1, 2) . As such, the brain always has been considered both chemically and immunologically privileged. The principal defense at the BBB is provided by cerebrovascular capillary endothelial cells that are characterized by: 1) tight intercellular junctions, 2) a relative lack of fenestrations and pinocytotic vesicles, and 3) the expression of efflux transport proteins and metabolic enzymes (e.g., P-glycoprotein and cytochrome P450 enzymes). Endothelial cells are supported in this role by the end-foot processes of perivascular astrocytes that express specialized proteins involved in volume and ionic regulation (1, 2) .
Seizures are known to interfere with the integrity of the BBB. For instance, the escape of serum albumin into the interstitial fluid of the brain (extravasation), indicted by penetration of Evans blue dye into brain parenchyma, is routinely observed in experimental seizure models and human epileptic tissue. However, it is now apparent that the reverse may be true-that disruption of the BBB can promote seizures or exacerbate a preexisting epileptic state. Topical application of bile salts to the cerebral cortex of naive animals results in the extravasation of albumin, activation of glial cells, and the development of localized epileptiform discharges as a result of impaired potassium buffering by astrocytes (3, 4) . Leakage of serum proteins into brain parenchyma is also observed following intravenous mannitol administration and leads to a concurrent and often progressive increase in seizure frequency in chronic epileptic rats (5) . Mannitol also has been shown to elicit immediate seizures in patients undergoing deliberate osmotic disruption of the BBB prior to chemotherapy for the treatment of primary brain lymphomas (6) . This evidence puts a new complexion on the interplay between seizures and the BBB and challenges the traditional view that epilepsy develops entirely from within the confines of the barrier.
Two recent studies, one by Kim et al. and the other by Fabene and colleagues, have furthered the notion that external contributors to the pathogenesis of seizures may involve BBB disruption. In addition to the extravasation of serum albumin and impaired potassium buffering, these studies imply that compromising the integrity of the BBB triggers an immune response characterized by rapid influx of white blood cells into the cerebrovasculature and their escape into the extravascular compartment, which results in the precipitation of seizures.
Fabene et al. induced a short period of status epilepticus in mice by systemic injection of pilocarpine, which when terminated by diazepam, was followed by a latent period of 1-2 weeks and then the subsequent development of chronic, recurrent seizures. The investigators showed an elevated cerebrovascular endothelial cell expression of various vascular cell adhesion proteins, including intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), P-selectin, and E-selectin, in response to the pilocarpine challenge. This upregulation, in concert with the accompanying seizure activity, caused an increased adherence of both polymorphonuclear leukocytes (i.e., neutrophils) and polarized T-helper cells to the blood vessel wall. Adherence was mediated by interactions between VCAM-1 and P-selectin and their respective leukocyte surface proteins, α 4 -integrin and P-selectin glycoprotein ligand 1 (PSGL-1), and was diminished by selective antibody blockade. Fabene and colleagues then demonstrated that the initial status epilepticus could be effectively prevented by pretreatment with α 4 -integrin antibody and that after status epilepticus, administration of both α 4 -integrin and VCAM-1 antibodies reduced the frequency of spontaneous seizures and protected against the neuronal cell loss typically associated with pilocarpine-induced epileptogenesis. These intriguing findings were validated in α 4integrin and PSGL-1 knockout mice, which proved to be resistant to status epilepticus and exhibited a marked reduction of late-onset chronic seizures. Prepilocarpine depletion of neutrophils, induced by using a granulocyte-specific antibody, had a similar effect. Finally, Fabene et al. showed that BBB leakage associated with pilocarpine could be prevented by pretreatment with α 4 -integrin antibody and was absent in the α 4 -integrin and PSGL-1 knockouts. This elegant study clearly demonstrates the contribution of BBB permeability and the vascular adherence of leukocytes to acute seizure initiation and longer-term epileptogenesis in the pilocarpine model and supports previous evidence suggesting that BBB disruption is a prerequisite for pilocarpine-induced seizures (7) .
A subsequent paper by Kim et al. demonstrated that infection of the CNS by direct injection of lymphocytic choriomeningitis virus could result in fatal immunopathology, mediated by breakdown of the BBB and convulsive seizures. They showed that activation of CD8 + T-lymphocytes by transient contact with cells infected by the lymphocytic choriomeningitis virus in the subarachnoid space was sufficient to precipitate a chain of events involving the initial release of various chemokines, most notably CCL3, CCL4, and CCL5, which in turn, resulted in the localized influx of neutrophils and monocytes at 6 days postinfection. A release of cytokines from these inflammatory cells and their diffusion across the vascular endothelial cell layer compromised the BBB, permitting extravasation of leukocytes and the onset of fatal seizures. Depletion of myeloid cells prior to lymphocytic choriomeningitis virus infection minimized BBB disruption (as measured by the escape of serum proteins) and delayed seizure onset but did not avert seizure-associated lethality. In contrast, treatment with anti-CD8 antibody prevented seizures, suggesting that interventions targeting early mediators of the immune cascade may be more effective at halting an otherwise insidious process. These findings suggest that enhanced permeability of the BBB, resulting from an immune-mediated inflammatory response, is not simply a feature of exposure to seizure-inducing chemicals, such as pilocarpine, but may be an inherent and required characteristic of epileptogenesis in general.
It is widely acknowledged that prolonged clinical seizures are associated with a mildly elevated white cell count in the cerebrospinal fluid, but until now, this inflammatory response was assumed to be a consequence of the seizures rather than a possible cause. It now appears that leukocyte infiltration of the brain is allied to the onset of seizures and may even be a prerequisite for epileptogenesis. This observation has potential therapeutic applicability, although not necessarily for established epilepsy in which the damage arguably already has taken place and theoretically is irreversible, but rather in the area of disease modification (8) . It offers promise for the use of immunomodulatory agents in the aftermath of epileptogenic insults, such as traumatic brain injury and stroke. However, a more obvious and immediate application might be the opportunity to arrest acute status epilepticus as well as prevent the long-term sequelae (including epilepsy) associated with CNS infections.
Numerous bacterial, parasitic, and viral etiologies of epilepsy are recognized, most notably those affecting patients in the developing world. A recent study from rural Kenya reported that 18% of 5,000 acute pediatric admissions were seizure-related and over 80% of those were associated with infections, such as malaria and pyrogenic meningitis (9) . Even in developed countries, one-third of patients with herpes simplex virus encephalitis experience acute symptomatic seizures, and one-in-four survivors are subsequently diagnosed with epilepsy (10) . Immunosuppressive therapy may be counterintuitive in cases of epilepsy with infectious etiology; however, the work by SUMMARY: The authors report the use of dense two-dimensional microelectrode array recordings to characterize fine resolution electrocortical activity ("µEEG") in epileptogenic human cortex. A 16-mm 2 96 microelectrode array with 400-µm interelectrode spacing was implanted in five patients undergoing invasive EEG monitoring for medically refractory epilepsy. High spatial resolution data from the array were analyzed in conjunction with simultaneously acquired data from standard intracranial electrode grids and strips. µEEG recorded from within the epileptogenic zone demonstrates discharges resembling both interictal epileptiform activity ("microdischarges") and electrographic seizures ("microseizures") but confined to cortical regions as small as 200 µm 2 . In two patients, this activity appeared to be involved in the initiation or propagation of electrographic seizures. The authors hypothesize that microdischarges and microseizures are generated by small cortical domains that form the substrate of epileptogenic cortex and play important roles in seizure initiation and propagation.
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B asic research on the mechanisms underlying the generation of epileptic seizures has technical and conceptual problems when the work is performed at the interface of cells and neuronal networks of the human neocortex. In particular, progress has been hindered by the difficulty of concomitantly recording the electrical activity of single neurons and their surrounding local neuronal network before, during, and after epileptic seizures. Neuronal action potentials have been recorded experimentally from human cortex for several decades using single microelectrodes (1). This technique obviously can reveal the firing patterns of individual neurons in relation to the highly synchronous hyperactivity characteristic of epileptic seizures in the cortex but alone, does not allow determination of epileptiform activity in adjacent small domains of the neocortex. The microelectrode array used in the study by Schevon et al., however, is able to reveal when epileptiform activity occurs in one or more specific sites but not in other nearby sites. Furthermore, the two-dimensional relationship of the array can show when epileptiform activity is on contiguous electrodes or occurs in a more scattered pattern of electrode sites.
Changes in the electrophysiological characteristics of individual human neurons and the functional properties of their local synaptic circuits associated with acquired epilepsy are best studied at a biophysical level with in vitro systems. Brain slices prepared from cortical tissue after surgical resections to treat patients with intractable epilepsy are a potentially useful model. These in vitro experimental systems, however, obviously lack synaptic input from most of their normal or abnormal connections. More importantly, although brain slices may display some forms of hyper-excitability and hyper-synchrony, they do not generate spontaneous, recurrent electrographic seizures without the addition of convulsive drugs, even when the tissue is obtained from a human with severe epilepsy (2) . The ability to study electrical activity at many adjacent sites in the cortex of an awake human with epilepsy-under the conditions described here-is typically limited by the technical difficulty of recording the activity of many single neurons and/or isolated neuronal populations. The study by Schevon and coworkers uses a microelectrode array to analyze the local field potentials in various areas of the neocortex of patients undergoing invasive EEG monitoring for surgical treatment of intractable epilepsy. This approach has the potential of allowing researchers to obtain data simultaneously from single neurons and their local neuronal networks.
Schevon and colleagues obtained recordings from five patients with microelectrode arrays positioned within the boundaries of an intracranial grid. The microelectrode array could record from up to 96 different sites, with a 400-µm interelectrode spacing. The microelectrode array was capable of detecting normal versus abnormal electrical activity at each of the 96 independent, but adjacent, sites. Most of the microelectrodes in the array exhibited synchronous local field potentials, when EEG spikes were observed on the intracranial grid. Other types of rhythmic electrical activity also were observed on the microelectrode arrays, including "microdischarges," which were defined as localized epileptiform discharges present on one or a few adjacent recording electrodes in the array but not present on the intracranial EEG. When microdischarges occurred in repetitive, evolving patterns, they were defined as "microseizures." These events were seen in most of the patients and were characterized by a morphology, periodicity, and frequency that is similar to seizure discharges. A comparison of the electrical activity on the microelectrode array with the epileptiform discharges on the Epilepsy Currents, Vol. 9, No. 5 (September/October) 2009 pp. 151-152 Wiley Periodicals, Inc. C American Epilepsy Society intracranial grid, detected microseizures on the microelectrode array when EEG spikes were not seen on the intracranial grid. Thus, epileptiform activity was recorded within microdomains of epileptogenic neocortex although traditional EEG spikes were not present, suggesting epileptiform activity can occur within extremely small neuronal networks of the neocortex. This finding leads to the hypothesis that microdomains with elementary seizure-like activity are present within seizure-onset zones.
One question is whether these microseizure events represent actual abnormal activity linked mechanistically to seizure onset in an epileptogenic zone or whether they would have otherwise been seen in normal brain. Although the authors intended to position the microelectrode arrays in the tissue that was already identified as epileptogenic, one recording site was subsequently assessed as nonepileptogenic, and microseizures were not recorded in that tissue, which suggests that microseizures are not present in relatively normal or nonepileptogenic brain. Microseizures could build up before and even appeared to trigger frank seizures, supporting the hypothesis that microseizures, localized to only a few cubic millimeters, play a role in the initiation of full epileptic seizures.
A question raised by the authors is whether the highly focal nature of these events makes them similar to high-frequency oscillations or fast ripples that have been seen in human temporal lobe epilepsy with a different type of multi-electrode recording (3, 4) . Like these local field potentials, high-frequency oscillations are thought to be highly localized, but they are recorded within a much higher frequency band than used in this study. Although microelectrode arrays, such as those used in the study of Schevon et al., are amenable to the recording of electrical signals in a higher frequency band and would allow high-frequency oscillations and single action potentials to be analyzed, these authors focused on local field potentials. Nonetheless, it is intriguing to consider a possible relation between microseizures and high-frequency oscillations.
This paper offers insights into how small regions of human neocortex are active before and during actual epileptic seizures. The authors have proposed that the neocortex of an individual with epilepsy is heterogeneous, with some microdomains that are epileptogenic and other nearby microdomains that are not, which is similar to the findings of regions with high-frequency oscillations or fast ripples (3, 4) . It is unclear whether those areas that do not show microseizures, yet are near an area that does, are nonepileptogenic or whether all areas are similar and probabilistic factors determine which neurons participate in microseizures. To demonstrate that specific microdomains are epileptogenic and other immediately adjacent microdomains are not would require evidence that some microdomains repeatedly show microseizures, while other microdomains never show them (4) .
The microelectrode array approach offers considerable potential for future research, because these arrays could be used in animal models (i.e., control preparations) as well as human epilepsy. In both cases, an analysis of the electrophysiology of individual neurons within a brain slice preparation that was obtained from a cortical region adjacent to an area previously recorded with a microelectrode array could be performed. Thus, the use of microelectrode arrays provides a novel window through which to observe epileptiform activity of single neurons and nearby small neural networks in human patients with intractable epilepsy. When combined with well-established electrophysiological techniques used for examining the biophysics of seizure discharges in neurons, it may be possible to link molecular and cellular mechanisms to systems level phenomena and thus gain valuable new insights into the pathophysiology of epilepsy.
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